The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Adjuvant Chemotherapy in Non-Small Cell Lung Cancer

비소세포폐암의 보조항암화학요법

  • Kim, Dong-Wan (Department of Internal Medicine, Seoul National University College of Medicine)
  • 김동완 (서울대학교 의과대학 내과학교실)
  • Published : 2012.09.01
⟨ Previous Next ⟩

Abstract

Complete surgical resection is a potentially curable treatment for localized non-small cell lung cancer. However, unfortunately, a significant proportion of patients experience recurrence after curative intent operation. To reduce the rate of recurrence after surgery, adjuvant chemotherapy has been studied in a series of randomized trials. The aim of the present review is to summarize the expected survival benefit of adjuvant chemotherapy and to define the adequate target population of adjuvant treatment based on the results from large randomized trials.

Keywords

References

  1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717. https://doi.org/10.1378/chest.111.6.1710
  2. Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 1984;2:1352-1358.
  3. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE, Payne WS. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984;38:331-338. https://doi.org/10.1016/S0003-4975(10)62281-3
  4. Thomas P. Rubinstein L. Cancer recurrence after resection: T1 N0 non-small cell lung cancer: Lung Cancer Study Group. Ann Thorac Surg 1990;49:242-246. https://doi.org/10.1016/0003-4975(90)90145-V
  5. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials: Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909. https://doi.org/10.1136/bmj.311.7010.899
  6. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360. https://doi.org/10.1056/NEJMoa031644
  7. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003;95:1453-1461. https://doi.org/10.1093/jnci/djg059
  8. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253. https://doi.org/10.1200/JCO.20.1.247
  9. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727. https://doi.org/10.1016/S1470-2045(06)70804-X
  10. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597. https://doi.org/10.1056/NEJMoa043623
  11. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010;28:29-34. https://doi.org/10.1200/JCO.2009.24.0333
  12. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559. https://doi.org/10.1200/JCO.2007.13.9030
  13. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-5051. https://doi.org/10.1200/JCO.2008.16.4855
  14. Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005;23:4999-5006. https://doi.org/10.1200/JCO.2005.09.017
  15. Goss GD, Lorimer I, Tsao MS, et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol 2010;28(18 Suppl):LBA7005.
  16. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991. https://doi.org/10.1056/NEJMoa060570